1198444
1206367
1206379
H3D Vision & Mission
Vision: To be the leading organisation for integrated drug discovery and development on the African continent Mission: Discover and develop innovative, life saving medicines For African patients Through excellence in interdisciplinary,...
H3D Facilities
Facilities H3D has state of the art laboratory equipment and access to modern instrumentation housed in the Department of Chemistry, the Department of Clinical Pharmacology and the Institute of Infectious Disease and Molecular Medicine (IDM) at UCT...
R&D Environment
UCT offers a truly integrated environment for translational research in communicable and non communicable diseases afflicting people in Africa. It has both the infrastructure as well as numerous groups working on pre-clinical and clinical research...
Home > Home

News

Thursday, 21 September 2017
H3D chemists in the lab
UCT’S DRUG DISCOVERY AND DEVELOPMENT CENTRE, H3D, IDENTIFIES A SECOND POTENT ANTI-MALARIAL CANDIDATE

The University of Cape Town (UCT)’s Drug Discovery and Development Centre, H3D, has identified a new potent anti-malarial development candidate with potential for both treatment and prevention of malaria

Publication Date:
Wednesday, July 27, 2016 - 16:30
Samples in incubator
ACCESS TO INNOVATION FOR ALL: IS IT POSSIBLE?

Maison de la Paix, Chemin Eugène-Rigot 2, 1202 Geneva

Please join us at this year’s World Health Assembly for a conversation with product developers on developing and scaling essential
health technologies. This moderated panel discussion will explore the current challenges of incentivising the development of innovative technologies that address the burden of disease globally, specifically poverty related and neglected diseases, while ensuring they are accessible to those most in need. Representatives from industry, academia, and nonprofit product development partnerships will debate the most significant barriers to access, and share successes, challenges, and lessons learned from a product developer’s perspective.

Publication Date:
Thursday, May 12, 2016 - 16:15
UCT’S H3D PARTNERS WITH JANSSEN PHARMACEUTICAL COMPANIES TO ADVANCE DRUG DEVELOPMENT IN AFRICA

The University of Cape Town’s Drug Discovery and Development Centre, H3D, has entered into a strategic partnership with Janssen Pharmaceutica N.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), aimed at jointly identifying and addressing the unique issues of advanced drug development in Africa.

Publication Date:
Wednesday, April 6, 2016 - 16:00
BAYER LINKS WITH ACADEMIA ON TB RESEARCH

The Universities of Dundee (Scotland) and Cape Town (South Africa) have linked up with the industrial expertise of the pharmaceuticals division of Germany’s Bayer (BAYN: DE), in an effort to develop critically needed new treatments for tuberculosis (TB). The collaboration combines some of the world’s best knowledge on TB biology, drug discovery and medicinal chemistry, with access to an industrial library of chemical compounds.

Publication Date:
Tuesday, March 8, 2016 - 11:15

Pages